Olaparib significantly suppressed RAD51C‐deficient tumour growth in a xenograft model.49 In addition, RAD51C promoter methylation was demonstrated to be associated with PARP inhibitor response in a PDX model.19 The gene discussed is RAD51C; the disease is neoplasm.